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With the cell therapy industry continuing to grow, the ability to preserve clinical grade cells, including
mesenchymal stem cells (MSCs), whilst retaining cell viability and function remains critical for the
generation of off-the-shelf therapies. Cryopreservation of MSCs, using slow freezing, is an established
process at lab scale. However, the cytotoxicity of cryoprotectants, like Me2SO, raises questions about the
impact of prolonged cell exposure to cryoprotectant at temperatures >0 C during processing of large cell
batches for allogenic therapies prior to rapid cooling in a controlled rate freezer or in the clinic prior to
administration. Here we show that exposure of human bone marrow derived MSCs to Me2SO for 1 h
before freezing, or after thawing, degrades membrane integrity, short-term cell attachment efﬁciency
and alters cell immunophenotype. After 2 h's exposure to Me2SO at 37 C post-thaw, membrane integrity
dropped to ~70% and only ~50% of cells retained the ability to adhere to tissue culture plastic. Further-
more, only 70% of the recovered MSCs retained an immunophenotype consistent with the ISCT minimal
criteria after exposure. We also saw a similar loss of membrane integrity and attachment efﬁciency after
exposing osteoblast (HOS TE85) cells to Me2SO before, and after, cryopreservation.
Overall, these results show that freezing medium exposure is a critical determinant of product quality
as process scale increases. Deﬁning and reporting cell sensitivity to freezing medium exposure, both
before and after cryopreservation, enables a fair judgement of how scalable a particular cryopreservation
process can be, and consequently whether the therapy has commercial feasibility.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cell therapies hold the potential to revolutionise healthcare as
regenerative medicines, replicating the success of the human
therapeutic protein industry. However, cell therapies are more
complex than protein therapeutics, which to the makes the pres-
ervation, long-term storage and shipment of cellular therapies a
challenging prospect. Cryopreservation methods for long-term
storage are described only in brief when reported in cell therapy
clinical trial protocols. For example, while a cooling rate may behuman mesenchymal stem
; pNNP, p-nitrophenyl phos-
an).
r Inc. This is an open access articleprovided, processing times before freezing or after thawing are
rarely given [13].
Components commonly used in lab-based cryopreservation
protocols, including animal serum and dimethylsulfoxide introduce
commercial, safety and regulatory risks for new therapies [38].
Animal-component free cryopreservation solutions are already
available, such as the CryoStor® range from BioLife Solutions and
PrimeXV®-FreezIS from Irvine Scientiﬁc. However, with cell-based
therapeutics approaching the critical Phase III stage of develop-
ment, there is a clear need to develop cryopreservation processes
that operate at meaningful scale, and which integrate with other
stages of an overall bioprocess. A well-integrated cryopreservation
process enables the decoupling of commercially scaled cell therapy
manufacture from ﬁnal delivery and administration to patients.
This in turn allows more cost-effective supply chain strategies for
initial cell banking of isolated donor material, as well as the ﬁnal
product. The ideal result is an inventory of well-stored andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
T.J. Morris et al. / Cryobiology 73 (2016) 367e375368consistent cell therapy product, which can be globally distributed
and administered at an affordable cost.
Human mesenchymal stem cells (hMSCs) are the most likely
candidates for early successful human stem cell therapies, with
hundreds of clinical trials evaluating their therapeutic potential
[39]. MSCs are multipotent; relatively easy to isolate; have the ca-
pacity for self-renewal and proliferation and are undergoing
assessment for a number of therapeutic indications including
immunological, cardiac and musculoskeletal conditions [17,28].
From a manufacturing perspective, clear deﬁnition of critical
quality attributes and a link to a therapeutic mechanism of action
(MoA) is necessary. Unfortunately, the complexity of MSCs and
diversity of patients and individual disease progression has resul-
ted in a lack of clarity around MoA for these therapies [4]. A variety
of potency assays have been developed for some therapeutic in-
dications, but at present there is no consensus on which should be
used for a given cell type and therapeutic indication. The Interna-
tional Society for Cellular Therapy (ISCT) recommends a minimal
hMSC speciﬁcation as being adherent to culture plastic; positive
(95%) for the expression of CD73, CD90 and CD105, negative
(2%) for the expression of CD14, CD19, CD34, CD45 and HLA-DR,
and possessing the capacity to differentiate towards the chondro-
genic, adipogenic and osteogenic lineages in vitro [8]. These
guidelines continue to be widely used to specify identity assays for
MSCs.
Using cryopreservation to decouple production and delivery of
hMSC-based therapies is a popular strategy, as demonstrated by a
2013 survey highlighting that over 80% of MSC-based regulatory
submissions used cryopreservation to store and transport the ﬁnal
product [23]. For example, Prochymal® (Mesoblast, USA), which has
been conditionally approved for use in children with graft-versus-
host disease in New Zealand and Canada, is stored in 15 mL Cry-
ocyte bags with 10% (v/v) Me2SO [14]. However, recent reports have
suggested that cryopreserved cells do not perform as well thera-
peutically compared with freshly cultured cells [10,25]. Cryopres-
ervation may be one of the reasons, as well as in vitro cell age, why
several recent hMSC clinical trials have failed to reach their primary
end-points, in contrast to earlier academic-led trials using freshly
cultured cells. Given the technical nuances of cryopreservation, it is
important to determine whether transient loss of cell function is an
unavoidable feature of cryopreservation, or whether it is caused by
aspects of the process that differ with process scale.
Me2SO has been used as a cryoprotectant since the 1950s [21],
but there is some evidence of rare but signiﬁcant adverse effects in
patients, including strokes, heart attacks and haemorrhages after
infusion with bone marrow cryopreserved in 10% (v/v) Me2SO [6].
Notably, not all adverse reactions can be directly attributed to
Me2SO [34] and the FDA Guidance for Human Somatic Cell Therapy
and Gene Therapy [37] does not prohibit the use of Me2SO as a CPA.
However, there is a perception that minimizing exposure of cells to
Me2SO will mitigate infusion-related effects in patient and impor-
tantly, Me2SO is also cytotoxic to human cells above 0 C and has
been linked to changes in differentiation capacity of stem cells
[1,9,36,43,44]. The mechanisms of Me2SO cytotoxicity are not well
deﬁned, but may be related to the enhanced diffusion of other
molecules, including toxins, across cell membranes [42], or through
destabilisation of normal ionic homeostasis. The use of Me2SO and
other permeating cryoprotectants must be managed carefully to
minimise the transplantation of poorly functioning cells; dead
cells; cell debris or potential cytotoxins into patients.
Cells are often processed in small batches for routine research
using passive slow cooling devices (e.g. Mr. Frosty™ or CoolCell®),
with modest cell densities around 1  106 cell/mL and cells being
kept on ice until transfer into their cooling device. However,
working cell banks for manufacturing can contains hundreds ofvials and allogeneic therapies are expected to require lot sizes of
1 109 or 1 1010 cells to meet market demands at affordable cost,
with each dose containing 5  107 - 2.5  108 cells [31]. Cryo-
preservation processes will therefore need to be in place to enable
preservation of large numbers of small cryovials for banking and
cryobags or larger vials (e.g. Crystal® or Daikyo Crystal Zenith®
vials) for cell product packaging. In both instances, processing
times will increase compared to lab scale and maintaining chilled
temperatures during vial ﬁlling and the particulate testing required
by USP <790> (Visible particulates in injections) for product vials is
an operational burden. This means that the detrimental effects on
cell quality of exposure to cryoprotectants like Me2SO will likely
impose limits to the achievable process scales for hMSC therapy
manufacturing. For example, it has been reported that for recom-
binant baby hamster kidney (rBHK) cells, cryopreservation bags
must be ﬁlled within a 2 h window to avoid adverse effects from
Me2SO exposure [15]. Similarly, Hunt et al. [16] showed that the
“recovery index”, a measure of viability from membrane integrity
and colony-forming-ability after thaw, of CD34 positive cells can be
reduced by as much as 50% when exposed to 25% (v/v) Me2SO for
up to an hour at 20 C. Katkov et al. [18] showed that human em-
bryonic stem cells lose around 50% expression of the vital Oct-4
marker after exposure to Me2SO using standard protocols. These
examples indicate that exposure of MSCs to Me2SO will need to be
limited in order to maintain therapeutically desirable cell charac-
teristics. Furthermore, these tolerances will need to be deﬁned and
built into not just manufacturing but also clinical practice. For
example, with product thawing and preparation for infusion or
injection the implications of failures in a thawing protocol or device
(e.g. long-term maintenance of the vial at > ambient temperature)
and delays in preparing the patient for treatment must be consid-
ered in order to develop preparation guidelines for the product. To
that end, we investigated the effect of Me2SO on cell quality by
exposing bone marrow derived hMSCs to this cryoprotectant for
varying amounts of time i) without, ii) prior to, and iii) after
employing standard freezing protocols. A maximum exposure time
of 2 h at ambient temperatures prior to freezing or at 37 C after
freezing was chosen to represent worst case scenarios. Results are
discussed in terms of the risk of product failure with cells consider
to be ‘overexposed’ to Me2SO once cell characteristics such as
attachment capability and phenotype fall below pre-deﬁned stan-
dards such as those set by the ISCT or FDA. Furthermore, the
sensitivity of hMSCs to Me2SO was compared to that of an
osteosarcoma-derived cell line, HOS TE85, to establish whether
hMSCs are more or less susceptible to Me2SO-induced effects than
similarly sized human cells.
2. Materials and methods
2.1. Cell culture
Osteosarcoma cells of the line HOS TE85 were acquired at pas-
sage 51 (ATCC, USA) and hMSCs derived from bone marrow at two
passages post extraction were cultured as adherent monolayers in
25 cm2 T-ﬂasks (Nunc, UK). hMSCs had been extracted from ethi-
cally sourced fresh bone marrow aspirate obtained from Lonza
(Lonza, Cologne AG) from a healthy donor after the patient pro-
vided informed consent. HOS TE85 cells were incubated in MEM
medium (a-MEM, 1 g/l glucose with 10% (v/v) US origin FBS (Per-
formance Plus) and 2 mM L-glutamine, (Thermo-Fisher, UK)), and
hMSCs in DMEM medium (made up in the same way with 1 g/L
glucose (Thermo-Fisher, UK) in place of a-MEM) in a humidiﬁed
incubator at 37 C, 5% CO2. Passaging was done every 2e3 days
(HOS) or 7 days (hMSC). A 100% medium exchange was done for
hMSCs on day 4. Spent-mediumwas collected before passaging for
Table 1
Antibodies used to detect surface markers. markers, their ﬂuorescein and associated
excitation and emission wavelength for the determination of hMSC phenotype.
Fluorophore Target surface marker antibody Max emission wavelength
PE-Cy5 CD34 667 nm
PE-Cy7 CD73 785 nm
APC CD90 578 nm
PE CD105 578 nm
FITC HLA-DR 519 nm
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EDTA. Samples were taken for cell counting and viability assess-
ment, then the remaining cells were centrifuged at 220 g for 5 min.
After aspirating the supernatant, the cell pellet was gently sus-
pended in freshmedium. Cells were then used to seed new ﬂasks at
2  104 cells/cm2 (HOS) and 5  103 cells/cm2 (hMSC).
2.2. Viable cell number
For HOS cells, 50 mL samples were taken andmixedwith 50 mL of
trypan blue stain (Sigma Aldrich, UK) then cells were counted
manually using a haemocytometer and light microscope. A Nucle-
ocounter NC-100 (Chemomotec, Denmark) was used to count
hMSCs, which measures membrane integrity using propidium io-
dide (PI). These two counting methods have been previously found
to be statistically similar [32].
2.3. Cryopreservation and thawing
For cryopreservation experiments, HOS cells were harvested
after 2 days in culture and hMSC cells were harvested after 7 days in
culture, using trypsin as described above in Section 2.1. After
centrifugation, trypsin containing medium was aspirated and the
resulting cell pellet was then suspended in freeze medium (10% (v/
v) Me2SO, 90% (v/v) FBS) at room temperature. 1 mL aliquots were
loaded into 1.8 mL cryovials (Nunc, UK). Cryovials were placed into
a CoolCell (BioCision, USA) and quickly transferred into a 80 C
freezer. This passively cooled the vials at approximately 1 C/
minute according to the manufacturer [2]. The total processing
time from harvesting to loading of the CoolCell into the freezer was
no more than one hour. After 4 h and no later than 24 h, cryovials
were stored in the vapour phase of a liquid nitrogen cryostorage
unit for at least 1 week.
Cryovials were retrieved from cryostorage then thawed in a
37 C water bath for 4 min. Thawed cells were then diluted 1:1 in
the vial, followed by 1:4 in 37 C pre-warmedmedium. Diluted cells
were then centrifuged, counted and seeded into 25 cm2 tissue
culture ﬂasks.
2.4. Experimental scheme
Cells were exposed to Me2SO following three different schemes.
For the ’just exposed’ group, cells were suspended in a freeze me-
dium at room temperature for 15, 30, 60 or 120 min, and then
washed and cultured with fresh culture medium, followed by
analysis for viability and attachment. In the ‘exposure þ freeze’
group, cells were exposed to Me2SO as per the “Just Exposed”
group, transferred to cryovials and then frozen with a passive
freezing device (1 C/min) (CoolCell, BioCision), stored in the
vapour phase of liquid nitrogen for one week and then thawed as
normal. For the ‘freeze þ exposure’ group, cells were frozen and
stored as described in Section 2.3, but after thawing were left at
37 C for 15, 30, 60 and 120 min before being washed in fresh
medium, cultured and analysed. After one passage, all groups were
analysed for growth, phenotype and metabolic activity, and then
cultured for four further serial passages and their growth, pheno-
typic and metabolic activity was compared.
2.5. Alkaline phosphatase assay for HOS TE85 phenotype analysis
Cells at a density of 2.5  106/mL were lysed with two freeze/
thaw cycles. In each cycle, cells were suspended in dH2O, trans-
ferred to a 20 C freezer for 24 h then warmed in a 37 C water
bath. 100 mL of cell lysate was transferred to a 48 well plate. Then,
300 mL of a working solution (1 (p-nitrophenyl phosphatesubstrate) pNPP tablet for every 5 mL, 1 part 20 mM MgCl2, 1 part
1.5 M Alkaline buffer solution and 7 parts dH2O) was added to the
lysate. This solutionwas incubated for one hour in the dark at room
temperature, before being quenched with 100 mL of 3M NaOH.
100 mL of the sample was transferred to a 96-well plate and
measured with a plate reader at 405 nm absorbance. A standard
curve of p-nitrophenol in the working solution without a pNPP
tablet was used. All reagents were from Sigma-Aldrich, UK.2.6. Five colour ﬂow cytometry assay for hMSC phenotype analysis
This assay was carried out using a previously described protocol
[5]. Harvested cells were suspended at 5  105 cells/mL in medium
and 200 mL of cell suspension was added per well of a V bottomed
96-well plate (Corning, UK). The plate was centrifuged at 300 g for
5 min, the supernatant aspirated, and then the cells were re-
suspended in 200 mL of ﬂow cytometry staining buffer (R&D Sys-
tems, UK). The plate was centrifuged and the supernatant removed.
As per Table 1, 5 mL of each antibody (BD Biosciences, UK) was then
added to the cell pellets. The platewas then incubated in the dark at
room temperature for 30 min, before being centrifuged. Stained
cells were washed twice with staining buffer, then suspended in
200 mL of staining buffer. Data were obtained using a Guava®
easyCyte 8HT ﬂow cytometer (Merck Milipore, UK) equipped with
excitation lasers at 488 nm and 640 nm and running guavaSoft™
InCyte™ (v2.5) acquisition software. For each sample, a minimum
of 5000 (gated on forward/side scatter) events were recorded.
Spectral overlap compensation was determined using ﬂuorophore-
conjugated anti-mouse Ig,k antibodies. Analysis after acquisition
and compensationwas done with FlowJo v7.6.5. (Treestar, Inc, USA)
software. To analyse for co-expression of all ﬁve markers, serial
gating was used [5]. Gates were set ﬁrstly on the CD73þve/CD105þve
population, subsequently on the HLA-DR-ve/CD90þve and CD34ve/
HLA-DR-ve population (see Fig. 3E).2.7. Metabolic analysis
1 mL of spent mediumwas taken at the end of each passage and
before medium exchange for hMSCs. Glucose and lactate concen-
trations in the spent medium and fresh medium were measured
using a Nova Bioproﬁle FLEX® (Nova Biomedical, UK). Net metab-
olite uptake and production by the cells from culture were inferred.
The apparent yield of lactate from glucose [29] was calculated as
follows:
Y 0Lac=Glc ¼
D½Lac
D½Glc
where: Y'Lac/Glc ¼ apparent lactate yield from glucose, D[Lac] ¼ net
lactate production over a speciﬁc time period, D[Glc] ¼ net glucose
consumption over the same time period.
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After exposure/thawing an additional ﬂask was seeded to
evaluate attachment efﬁciency. After one hours' incubation, cells
were enzymatically detached from the culture vessel and counted.
Cell counts were normalised to the known seeding density to
determine attachment efﬁciency.2.9. Statistics
All statistical data analysis was performed using the SPSS
version 21 (IBM). Signiﬁcance was determined using a One Way
ANOVA test, followed by Dunnett's test for comparison with con-
trols. Values of p < 0.05 were considered to be statistically signiﬁ-
cant. All data quoted represent the mean of two duplicates from
three independent experiments, ± standard deviation (SD), unless
otherwise stated.3. Results and discussion
3.1. Impact of Me2SO exposure on cell viability and cell attachment
ability
HOS TE85s and early passage hMSCs were exposed to Me2SO as
described in Section 2.4 and membrane integrity as a proxy for
viability was subsequently measured either immediately after
exposure (just exposed group and freeze þ exposure groups) or
post-thaw (exposure þ freeze). The viability of the HOS TE85 and
hMSC cell populations decreased in a time-dependent manner
under all three conditions of Me2SO exposure (Fig. 1A and C).
Viability fell to ~70%when cells were exposed toMe2SO for 120min
once thawed after freezing (i.e. the ‘freeze þ exposure’ group). It is
noteworthy that the viability range exceeded the US FDA recom-
mended lower limit for membrane for therapeutic applicationsFig. 1. Viability with respect to membrane integrity and attachment efﬁciency of (A,C) HOS T
up to 120 min. Data are the mean ± SD derived from two duplicates from three independe[23,38]. These data indicate the importance of timing when car-
rying out the viability testing as part of release criteria as close to
point of administration as possible, rather than at the immediate
point of thaw (if these are to be different).
These results are similar to those reported by Hunt et al [16] who
found that CD34þ cells exposed to 25% (v/v) Me2SO for up to
20 min at 2 C showed negligible drop in viability, with loss of
viability observed only with increasing time and temperature of
exposure. However, the study is limited to Me2SO exposure only,
rather than the combination of exposure and freezing as shown in
this work. Here we show that none of the just exposure groups
(without cryopreservation) were statistically different from the
non-exposed controls. This suggests that it is the combination of
Me2SO exposure and the cumulative complications of freezing and
thawing, such as changes in osmolality during slow cooling and
rewarming, which results in the loss of membrane integrity, rather
than exposure to CPA per se.
It has been established that, although cells may appear viable
upon thaw based on simple measures of viability like trypan blue
exclusion, they may undergo delayed onset apoptosis [40]. For
example, Aye et al. [1], showed that after 3 h CHO cells exposed to
20% Me2SO still exhibit viability of over 90%, but after 24 h this was
reduced to just 10%. Therefore, cell attachment one hour after
seeding was also investigated as a potential indicator of cell sur-
vival. hMSC homing and engraftment in vivomight be necessary for
sustained clinical function [19]. Normal attachment efﬁciency one
hour after seeding is >85%, but both freezing and Me2SO exposure
time had impact on this response. The Frozen þ Exposure group
had the lowest attachment efﬁciency after two hours (Fig. 1C and
D), with just 65% attachment for HOS TE85 cells, and 53% for hMSCs,
a signiﬁcant reductions of 21% and 46% respectively. Signiﬁcant
drops in attachment from the un-exposed controls were observed
in the HOS TE85 120 min Freeze þ Exposure group, and in hMSC 60
and 120 min Exposure þ Freeze and Freeze þ Exposure group. CellE85 and (B,D) hMSC cells after exposure to Me2SO before and after cryopreservation for
nt experiments.
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it is one of the three key criteria for MSC identity proposed by
Dominici et al., in 2006 [8], and perhaps the simplest to observe and
quantify. Pal et al. [27] have previously noted unquantiﬁed
abnormal cell attachment of stem cells after Me2SO exposure for
24e48 h at low concentrations, 0.01% (v/v), 0.1% (v/v) and 1% (v/v)
[27]. The data here also show that cell populations have an
observed viability based on membrane integrity after thawing, but
that this does not correlate to the number of cells that had adhered
to tissue culture plastic one hour after seeding. The latter should be
a more stringent metric of viability, as cell adhesion and spreading
are reliant on active processes including actin ﬁlament formation
[26] and energy metabolism. Furthermore, the proteolysis of
cytoskeletal components, whichmaintain cell shape and are crucial
for cell-surface attachment, is one of the ﬁrst stages of delayed-
onset apoptotic cell death commonly seen after cryopreservation
[35]. Using attachment efﬁciency might therefore be a better
candidate benchmark for release from the manufacturing site, as it
relates better to MSC health and identity after recovery from
cryopreservation. It was clear that using the same 70% threshold
shows that cells reach this level of acceptability after around 1 h of
exposure to Me2SO and indicates that any longer than this would
constitute overexposure as cell function is affected.
3.2. Impact of Me2SO exposure on cell growth
Me2SO has previously been shown to affect cell proliferation
both negatively [35] and positively [30]. Therefore, to assess the
potential for longer-term impact of Me2SO exposure on cell quality,
hMSC and HOS TE85 cell proliferation and basic metabolic proﬁles
(Section 3.3) were assessed over multiple passages post-exposure.
When growth over one passage post-thaw was investigated,
there was no statistically signiﬁcant effect of anyMe2SO treatments
on HOS TE85 cells (Fig. 2A and B). The lack of a signiﬁcant impact on
growth rate indicates that in addition to the cells' quick recovery on
thaw, Me2SO has a limited effect on growth capability of osteo-
sarcoma cells once washed away.
The hMSCs also showed a downward trend in growth with
increasing exposure time (Fig. 2C), across all three treatment
groups. However, only the Freeze þ Exposure 60 and 120 min
groups were statistically different from the non-exposed control.
This lag in growth rate over the ﬁrst passage post-thaw may be an
important consideration for the therapeutic use of cryopreserved
hMSCs, as engraftment and expansion in-vivo have direct bearing
on the potential mechanisms of action clinically. Delayed
outgrowth may also be an issue when hMSCs are banked in read-
iness to seed subsequent culture vessels for expansion as part of a
cell therapy manufacturing process. The increased time required to
achieve a desired cell yield directly increases costs. Furthermore,
the loss of cells early in the process lowers the potential expansion
headroom per banked vial, restricting the scale of manufacturing.
It is also important to consider growth over several passages in
order to assess whether Me2SO exposure has any sustained long-
term impact on cells. This is important for cell therapies if the
cells need to persist in the body for several days, or integrate into
the host tissue and differentiate for their therapeutic effect. The
HOS TE85 cells were cultured for ﬁve serial passages to see what
effect Me2SO had on long-term growth of these cells. Fig. 2C shows
that over the 5 passages (at least 12 doublings), there was no sig-
niﬁcant difference between any of the treatment groups. Baseline
experiments on HOS TE85 cells (data not shown) demonstrated
that the exposed cells behaved in a similar fashion to the non-
exposed groups. Consequently, we saw no long-term impact on
HOS TE85 proliferative capacity or culture growth rate.
Human MSCs from the Just Exposure group were also culturedover 5 passages and as shown in Fig. 2D signiﬁcant differences from
the non-exposed control were observed in the 120 min group,
further conﬁrming that exposure of this time frame to Me2SO
causes a signiﬁcantly detrimental effect on hMSC growth. Notably, a
correlation of attachment to long term growth of 0.9704 was
observed (Fig. 2E), indicating that a 1 h attachment efﬁciency assay
reﬂected the longer-term growth potential for hMSCs which obvi-
ates the need for protracted outgrowth studies in future. Indeed, a
short-term attachment efﬁciency assay has previously been used to
successfully predict proliferative potential with human embryonic
stem cells (hESCs) [24].
We therefore propose that cell attachment after 1 h is strongly
correlated (Fig. 2E) with long-term expansion potential of the cell
types cultured herein. This suggests that the impact of any delayed
onset cell death is minimal if one wishes to culture cells in vitro.
Clearly, there is potential for donor and processing variability, and
this correlation should be explored during early product develop-
ment to conﬁrm its predictive value where cell expansion is a key
part of a cell therapy bioprocess. However, it is not clear whether a
correlation between in-vitro adhesion efﬁciency and expansion can
be predictive of cell adhesion and retention in-vivo during cell
therapy delivery. Mechanistically, this correlation is explained by
the simple fact that these cells require adhesion to a surface before
they can replicate. Fewer adherent cells mean a smaller effective
seed population, with subsequent impact on long-term expansion
potential in the absence of changes to the mean cell proliferation
rate. This allows for a much quicker analysis process-weeks
compared to 1 h for determining the long-term effect growth on
cells (via colony forming unit counts).
3.3. Impact of Me2SO exposure on cell metabolism
During addition and removal of cryoprotectant solutions, slow
cooling and rewarming, cells are subjected to changes in osmolality
and volume, with the latter being linked to changes in metabolism
[20]. Furthermore, mitochondrial andmetabolic changes have been
shown to occur during stem cell differentiation [41], highlighting
that process conditions that alter MSC metabolism could inﬂuence
their function. As such, ofﬂine metabolic sampling during post-
thaw expansion could provide early warning of detrimental
changes. These could then be evaluated more closely with more
laborious assays focusing on speciﬁc aspects of cell state. Accord-
ingly, spent medium was analysed for glucose and lactate at each
passage, and in the case of hMSCs at each medium exchange as
well, to assess whether cells exposed to Me2SO exhibited a change
in their metabolic proﬁle. From these data, the metabolic yield of
lactate from glucose can be calculated and monitored. The
maximum theoretical yield of lactate from glucose is 2 mol/mol.
Values lower than this indicate glucose is being diverted elsewhere
whereas values > 2 mol/mol indicate lactate is being generated
from a non-glucose source [11].
For the HOS TE85 cells, a control value of glucose yield from
lactate was shown to be 1.403 mol/mol (Fig. 3A) based on cells
grown in continuous culture. None of the exposed groups were
signiﬁcantly different from the non-exposed control, indicating
that there was no substantial change in glucose or lactate cell
metabolism after freezing or Me2SO exposure. However, there was
variation across the hMSC groups (Fig. 3B). The hMSCs exposed
after thaw for 60 min (Freeze þ Exposure), and all three 120 min
exposure groups were statistically signiﬁcantly different from the
non-exposed control. This indicates that 1 h or more of exposure to
Me2SO can inﬂuence the subsequent hMSCs metabolic proﬁle
during in-vitro expansion.
All exposed groups except the 15min “Just Exposure” groups are
above the 2 mol/mol theoretical yield limit, indicating the cells are
Fig. 2. Daily fold expansion rate over one passage and total fold expansion rate over 5 passages (A,C) HOS TE85 and (B,D) hMSC cells after exposure to Me2SO before and after
cryopreservation for up to 120 min. Data derived from two duplicates from three independent experiments. Error bars represent standard deviation.* indicates statistical signif-
icance (p < 0.05) from the respective non-exposed group. Error bars are standard deviation. E: Normalised data of 1 h attachment efﬁciency and ﬁve serial passages of hMSC cells
after exposure to Me2SO for up to 120 min and then washing.
T.J. Morris et al. / Cryobiology 73 (2016) 367e375372converting an additional energy source to lactate, which is likely to
be glutamine in the growth medium. This has been previously
noted and proposed by Raﬁq et al. [29] and perhaps indicates a less
severe metabolic change than that experienced in the 60 min and
120 min groups. Furthermore, any change in metabolic proﬁle
could indicate that the cells are stressed or differentiating, and
therefore cannot grow as efﬁciently, hence phenotype was
assessed.3.4. Impact of Me2SO exposure on cell phenotype
Both cell types were cultured for one passage before phenotype
analysis occurred, allowing any long-term phenotypic effect to be
revealed. HOS TE85 phenotype was analysed by using an alkaline
phosphatase (ALP) assay. ALP activity is indicative of a cells ability
to mineralise bone, as it increases the local concentration of inor-
ganic phosphate and decreases the concentration of extracellular
pyrophosphate, which is an inhibitor of mineralisation [12]. While
HOS TE85s are osteocarcoma cells and not true osteoblasts, baselineexperiments (data not shown) showed that these cells retained
some ALP activity in culture. Longer exposure to Me2SO lowered
ALP activity per cell, indicating a detrimental change in the osteo-
blastic phenotype (Fig. 3C). A reduced expression of ALP has pre-
viously been reported in pancreatic cells after exposure to Me2SO
[22].
When we consider the hMSCs, the expression of ﬁve extracel-
lular markers was investigated; the co-expression of these is shown
in Fig. 3D. There was a change in the phenotype away from the ISCT
criteria [8] across all three groups as Me2SO exposure time in-
creases, with signiﬁcant loss of phenotypic marker expression in
the three most extreme conditions. Therefore, exposure to Me2SO
beyond an hour has a substantial negative effect on the hMSC
phenotype after the cryopreservation process and thus constitutes
overexposure. This may also indicate that Me2SO is promoting
differentiation of hMSCs. As Me2SO has been used in conjunction
with retinoic acid and 5-azacytidine to promote cardiac differen-
tiation of human foetal liver-derived MSCs and can induce differ-
entiation of human embryonic stem cells [7,18,27]. Although not
Fig. 3. Metabolic yield of lactate from glucose and phenotype data of (A,C) HOS TE85 and (B,D) hMSC cells after one passage in culture post exposure to Me2SO before and after
cryopreservation for up to 120min. Data derived from duplicates from three independent experiments. Error bars represent standard deviation.* indicates statistical signiﬁcance
(p < 0.05) from the respective non exposed groups. Phenotype Data derived from C: Alkaline Phosphatase Expression and D: Immunophenotype expression of CD73, CD105, CD34
and HLA-DR. E: Dot plots showing the serial gating method applied to Exposure þ Freeze 15 min group.
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phenotype was enhanced when cells were frozen. This indicates
that factors such as osmotic stress and the changes in metabolism
noted earlier in these groups may also affect phenotype. This is
consistent with the fact that metabolic changes have previously
been shown to occur during stem cell differentiation [41]. However,
that phenotypic expression signiﬁcantly differed from the hMSC
standard after 120 min Me2SO exposure, but cell viability on thaw
was above the FDA's recommended minimum 70% viability criteria
[4] raises the question whether on thaw viability is a reasonable
release criteria in the absence of other indicators.
4. Conclusion
The successful cryopreservation of human cells is necessary to
enable the production of off-the-shelf cell therapies, but challenges
remain to retain cell functionality at commercial scale. Preventing
changes to phenotype and metabolism is vital for cell therapeutics
including hMSCs, which have been described by Caplan and Correa
[3] as a “drugstore” for injury with the ability to establish a
regenerative microenvironment through secreted protein factors,
which regulate the local immune response at the injury site. If the
cells are not what the physician or patient expects and cells have
lost their therapeutic function or are unable to engraft, then pa-
tients will have been given at best an expensive placebowith added
risk of harm.
However, working cell banks for manufacturing can contains
hundreds of vials and with cellular therapeutics requiring
>109 cells per dose [31] and with these increased volumes the cell-
cryoprotectant exposure time will increase as the process scales
from a laboratory to manufacturing environment. Limits on cryo-
protectant exposure time, which will vary depending on the cell
source as well as the upstream processing, may drastically reduce
the scale of manufacture per batch. Hence we looked at two worst
case scenarios using hMSCs and have shown that overexposure to
Me2SO, found here to occur with >1 h exposure prior to or after
freezing, had a signiﬁcant effect on cell metabolism and altered
phenotype. We believe that these limits need to be accounted for
when designing a larger scale manufacturing process and when
training clinical staff in the thawing and use of cells preserved in
Me2SO to minimise the risk of product failure. For example, ac-
cording to USP <790> (Visible Particulates in Injections) all vials of
injectables need to be visually inspected for particulates and this a
time consuming element of production, with chilling of vials prior
to inspection adding to the burden due to condensation on the
outside of the vials. Our data indicates that for products packaged in
1.5e5 mL cryovials, if a semi-automated vial ﬁlling systems such as
the CellSeal® system fromCook RegenTecwas being used to ﬁll vials
at a speed of 10 vials per 1e2min, thesewould potentially not need
to be chilled prior to particulate testing, especially if ﬁlling and
testing could be co-located to ensure the vials were processed
within this hour timeframe. Notably, similar trends were also seen
with an osteoblast (HOS TE85) cell line indicating these results are
not unique to MSCs. Deﬁning the cell sensitivity to cryoprotectant
exposure will be crucial to allow sensible decision-making with
regard to larger-scale process design, including batch sizing and
selection of equipment to meet processing requirements within a
well-deﬁned processing window. As there must be some exposure
of cells to cryoprotectant post-thaw, controlling pre-freeze expo-
sure is also essential to provide a safety-margin for exposure time
during processing and removal of cryoprotectant after thawing, as
the effects of cryoprotectant exposure will be cumulative. As such,
tackling the issue of Me2SO toxicity, by providing alternatives such
as non-permeable sugars like Trehalose, in combination with per-
meabilising polymers [33], or negating the issue will be importantfor the commercialization of cell therapies.
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